Company intelligence / Profile preview
OX2 Therapeutics
Minnesota, United Statesox2therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting a Phase 1 clinical trial for CD200AR-L in combination with imiquimod and GBM6-AD vaccine to treat recurrent glioblastoma. Previous studies showed increased anti-tumor response in mice and 20% two-year progression-free survival in dogs with glioma.
- Therapeutic areas
- Oncology
- Modalities
- Peptide checkpoint inhibitorsRecombinant polypeptide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on OX2 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OX2 Therapeutics.